MedTrace Logo

Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application

NCT06233357 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 95

Last updated 2024-02-01

No results posted yet for this study

Summary

In a retrospective observational study, critically ill COVID-19 patients admitted to the ICU with the CoV-2 delta-variant between august 2021 and february 2022 were evaluated (ethics application nr. 129/22 of the ethics commssion of the university Ulm.

Conditions

  • COVID-19
  • Outcome, Fatal
  • Tocilizumab
  • Interleukin 6
  • Critically Ill

Interventions

DRUG

treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)

IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP \> 75 mg/l or IL-6 \> 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight

Sponsors & Collaborators

  • University of Ulm

    lead OTHER

Principal Investigators

  • Manfred Weiss, MD · University of Ulm

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2022-04-28
Completion
2023-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06233357 on ClinicalTrials.gov